Investors Purchase Large Volume of Atossa Therapeutics Call Options (NASDAQ:ATOS)

Share on StockTwits

Atossa Therapeutics, Inc. (NASDAQ:ATOS) saw unusually large options trading activity on Wednesday. Traders purchased 2,603 call options on the stock. This represents an increase of 300% compared to the average volume of 650 call options.

Several research firms have issued reports on ATOS. Maxim Group restated a “buy” rating and issued a $8.00 price target on shares of Atossa Therapeutics in a research report on Friday, September 18th. Ascendiant Capital Markets assumed coverage on shares of Atossa Therapeutics in a research report on Thursday, September 17th. They set a “buy” rating and a $7.00 target price on the stock.

A hedge fund recently raised its stake in Atossa Therapeutics stock. Morgan Stanley boosted its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 119,497.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 131,557 shares of the company’s stock after purchasing an additional 131,447 shares during the period. Morgan Stanley owned about 1.27% of Atossa Therapeutics worth $318,000 at the end of the most recent quarter. 6.87% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Atossa Therapeutics stock opened at $1.18 on Thursday. The firm’s 50-day simple moving average is $1.11 and its 200-day simple moving average is $2.31. Atossa Therapeutics has a twelve month low of $0.76 and a twelve month high of $5.08. The firm has a market cap of $12.38 million, a P/E ratio of -0.87 and a beta of 2.34.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Wednesday, November 18th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.01.

About Atossa Therapeutics

Atossa Therapeutics, Inc develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer.

Read More: Is a Roth IRA right for you?

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with's FREE daily email newsletter.